156 results about "Inosamycins" patented technology

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

The present invention provides a bone marrow stem cell protection solution, which is mainly prepared by dissolving a hypoxic protection agent, heparin sodium and an aminoglycoside antibiotic in a DMEM/F12 culture medium aqueous solution, wherein per mL of the DMEM/F12 culture medium aqueous solution can respectively dissolve 5-10 mg of the hypoxic protection agent, 0.01-0.05 U of the heparin sodium and 50-200 U of the aminoglycoside antibiotic, and the concentration of the DMEM/F12 culture medium aqueous solution is 30-40 mg/ml. According to the present invention, the bone marrow stem cell protection solution has advantages of stable performance, safety and no toxicity, can effectively protect bone marrow stem cells, can make bone marrow stem cells be preserved for a long time and can maintain the cell activity in vitro, can maintain the original multidirectional differentiation ability, and can expand the clinical application of bone marrow stem cells, wherein the bone marrow stem cells can be transported to most domestic cities and neighboring countries by using the existing transportation tools.

The invention discloses a preparation method and an application of a sensor for simultaneously detecting four aminoglycoside antibiotics and belongs to the technical field of novel function materials and biosensor analysis. According to the invention, a reference electrode is printed by the use of a silver paste and four working electrodes and a counter electrode are printed by the use of a conductive carbon paste on a rectangular substrate surface coated with a layer of a polyester film. Thus, a four-channel screen-printed electrode is prepared. The preparation method is characterized in that antibodies of four aminoglycoside antibiotics including streptomycin, gentamycin, kanamycins and spectinomycin are respectively fixed on surfaces of the four working electrodes by the use of a Pt nanoparticle-sulfated graphene-carboxymethyl chitosan conductive composite nano-material; and after the detection liquids are dripped, the four working electrodes are connected with a multichannel electrochemical workstation detection circuit so as to realize simultaneous detection of the four aminoglycoside antibiotics. The sensor provided by the invention is simple to prepare and convenient to process, requires low cost, and is convenient to carry. The detection method is simple and rapid and has high sensitivity and good specificity.

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).

This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.

DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3′-end of the broken DNA. Tyrosyl-DNA phosphodiesterase (Tdp1) can repair Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. Inhibiting Tdp1 has the potential to enhance the anticancer activity of Top1 inhibitors and to act as antiproliferative agents. It has been recently reported that neomycin inhibits Tdp1 more effectively than the related aminoglycosides paromomycin and lividomycin A. Inhibition of Tdp1 by neomycin is observed both with single- and double-stranded substrates but is slightly stronger with duplex DNA, which is different from aclarubicin, which only inhibits Tdp1 with the double-stranded substrate. Inhibition by neomycin can be overcome with excess Tdp1 and is greatest at low pH. Aminoglycoside antibiotics and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first reported pharmacological Tdp1 inhibitors. The development of Tdp1 inhibitors as anticancer agents can be envisioned as combinations of Tdp1 and Top1 inhibitors. Moreover, Tdp1 inhibitors might also be effective by themselves as anticancer agents. In addition, Tdp1 inhibitors might be valuable as anti-infectious agents.

This invention can produce a co-encapsulated combination drug product consisting of a topoisomerase 1 inhibitor such as camptothecins including neat camptothecin and its derivatives irinotecan, topotecan and other derivatives, and a tyrosyl-DNA phosphodiesterase (Tdp1) such as aminoglycoside antibiotics including neomycin and tetracycline, and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin.

The invention relates to a kit for quickly detecting a drug resistance gene of pneumophila pathogenic bacteria, which comprises a gene chip capable of detecting 24 main drug resistance genes of pneumophila pathogenic bacteria and a reaction system for multiple asymmetric PCR reactions. The 24 drug resistance genes are derived from aminoglycosides, quinolones, extended spectrum beta-lactamases (ESBLs), cephalosporins (AmpC), carbapenems and drug resistance genes with vancomycin resistance and methicillin resistance causing membrane permeability transition. The kit can be used for directly detecting drug resistance genes of pneumophila pathogenic bacteria in clinical samples, is simple and quick to operate, does not need culture or drug sensitive tests, gains valuable time for reasonable application of antibiotics to a great extent, and is worthy of clinical popularization and application.

The invention discloses an animal bifidobacterium and a composition thereof, and belongs to the technical field of microbe application. The preservation number of the animal bifidobacterium provided by the invention is CGMCC No.4521 and is preserved in General Microbiology Center of Chinese Culture Collection Committee in Beijing on December 29, 2010. The animal bifidobacterium provided by the invention has a symplastic growth effect on lactobacillus casei, streptococcus faecium and bacillus cereus and has tolerance on carbostyril, aminoglycoside and monocyclic beta-lactam antibiotics, and the animal bifidobacterium is suitable for use in food, drugs and/or health care products.

The invention provides a placenta and umbilical cord cell protective solution. The protective solution is mainly prepared by dissolving a mycoplasma inhibitor and aminoglycoside antibiotics with an aqueous solution of MEM-alpha medium. 1 mL of the aqueous solution of MEM-alpha medium is respectively used for dissolving 10-30 mg of the mycoplasma inhibitor and 180-240 U of the aminoglycoside antibiotics. Concentration of the aqueous solution of MEM-alpha medium is 10-15 mg/mL. The protective solution provided by the invention not only can effectively kill or inhibit formation of mycoplasma and prevent placenta cell or umbilical cord cell infection, but also can provide a stable osmotic pressure environment for placenta or umbilical cord cells through addition of protective components. Then, human environment can be effectively simulated, and cell survival rate is raised. Meanwhile, nutrients can be provided for storing and transporting cells within a short period of time; immune performance of cells is enhanced; cell infection is prevented; cell viability is effectively improved; and cell transport time is prolonged.

The invention relates to the microbial field, and discloses corynebacterium glutamicum strains and application thereof. A corynebacterium glutamicum MHZ-0510 strain has a preservation number CGMCC No.7939; a corynebacterium glutamicum MHZ-0511 strain has a preservation number CGMCC No.7940; the two strains have significantly improved ability of fermentation for generating L-glutamine, compared with that of the original strain of wild type of corynebacterium glutamicum B498, and can be widely applied to fermentation production of L-glutamine. The corynebacterium glutamicum strains involved in the invention are obtained by screening aminoglycoside antibiotics, such as streptomycin and neomycin, have resistance to the aminoglycoside antibiotics including streptomycin and neomycin, and have improved ability to synthesis of L-glutamine, thus increasing the yield of L-glutamine. Therefore, aminoglycoside antibiotics can be widely applied to screen of L-glutamine.

The invention discloses primers and a kit for detecting the aminoglycoside drug-resistance genes of bacteria, and belongs to the technical field of microbiological detection. The sequences of the primers provided by the invention are shown in SEQ ID NO: 1-10, and by comparing the aminoglycoside drug-resistance gene sequence of multiple bacteria and clinic isolated strains in the gene sequence library of NCBI, the specific primers designed at conserved sites are capable of rapidly detecting the five aminoglycoside drug-resistance genes of aac(3)-II, aac(6')-Ib, aph(3')-III, ant(3')-1a and ant(4')-1a5 of multiple bacteria. The invention further discloses a kit containing the primers and used for detecting the aminoglycoside drug-resistance genes of bacteria, wherein the kit is capable of rapidly and accurately detecting the aminoglycoside antibiotic-related drug-resistance genes of bacteria.

The invention relates to a slow-releasing agent of antibiotics containing aminoglycoside, comprising slow-releasing micro-sphere containing slow-releasing findings and aminoglycoside antibiotics, and special dissolvent containing suspending adjuvant agent such as sodium carboxymethyl cellulose with the adhesive degree being 100cp-3000cp (at 20-30 Deg. C). The slow-releasing findings comprises EVAc, polyphenyl, PLA, PLGA, decanedioic acid copolymer, albumen glue and gelatin; the slow-releasing micro-sphere can be produced to slow-releasing implanting agent and unguent agent. When the slow-releasing implanting agent and injection is placed or injected into bacteria, the medicine can be released slowly for more than 5-30 days, and toxicity is dramatically reduced at the same time when effective medicine concentration is got and maintained. The said slow-releasing agent is specially effective for chronic medullitis, bedsore, intractable ulcer on skin, diabetes femoral head necrosis and other abscessus, which are caused by Staphylococcus, Streptococcus, Streptococcus, acne Propionibacteriaceae, Enterobacter, Enterobacter, gonotoxin or parameningococcus.

The invention relates to an enzyme-linked immunodetection method of aminoglycoside antibiotics in animal-derived foods, belonging to the immnunoassay field. The invention utilizes a carbodiimide method to synthesize immunogen (NM)L-(KM)m-(GM)n-(SM)k-BSA with multiple antigen determinants, such as aminoglycoside antibiotics, by four steps, utilizes a glutaric dialdehyde method to synthesize the envelope antigen of the aminoglycoside antibiotics and establish the enzyme-linked immunodetection method of the aminoglycoside antibiotics in the animal-derived foods; a polyclonal antibody with the specificity of aminoglycoside cluster is adopted as a detection reagent; gentamicin, neomycin, kanamycin or streptomycin is adopted as a standard substance, the four antibiotics and OVA conjugate are adopted as the envelope antigens, and the establishment of an ELISA method for detecting multi-residue of the aminoglycoside antibiotics provides a detecting means with high speed and high efficiency for the multi-residue detection of the aminoglycoside antibiotics in the animal-derived foods. The invention has the advantages of simple pre-processing, high sensitivity, high precision and the like.

An antibacterial eye medicine containing pranoprofen contains non-steroid antiphlogistic medicine, aminoglycoside-type antibacterial medicine, polyvinyl pyrrolidone, and pharmacologically acceptable carrier. Its preparing process is also disclosed.

The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

This invention discloses a method of inducing expression of full-length collagen 7 in cells that contain nonsense mutations in the COL7A1 gene by treating the cell with an aminoglycoside such as G418, gentamicin, and paromomycin. Also provided is a method of treating DEB due to nonsense mutation in the COL7A1 gene by administering a composition containing an effective amount of an aminoglycoside. Also provided is a novel composition useful to treating conditions due to nonsense mutation in the COL7A1 gene, containing an aminoglycoside, a C7, a min-C7 or both; and a pharmaceutically acceptable carrier.